Lack of estrogen protection in amyloid-mediated endothelial damage due to protein nitrotyrosination

Running title: Nitrotyrosination in endothelial cells

M. Coma[1], F.X. Guix[1,2], I. Uribesalgo[1], G. Espuña[2], M. Solé[1], D. Andreu[2], and F.J. Muñoz[1,*]

[1]Laboratori de Fisiologia Molecular, Unitat de Senyalització Cel·lular and [2]Unitat de Proteòmica, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.

To whom correspondence should be addressed:

Dr. Francisco J. Muñoz,

Laboratori de Fisiologia Molecular, Unitat de Senyalització Cel·lular,

Universitat Pompeu Fabra,

Carrer Dr. Aiguader, 80, Barcelona 08003, Spain,

Fax: + 34 93 542 28 02; Phone: +34 93 542 28 84; e-mail: paco.munoz@upf.edu

Number of words in the text (excluding references, tables and figure legends): 4654

Key works: Alzheimer's disease; amyloid ß-peptide; nitric oxide; estrogen; nitrotyrosination.

Acknowledgements: This work was supported by grants from FIS (Ministerio de Sanidad, Spain; grant nº 01-1029; Red HERACLES; and Red de Centros de Cáncer), Fundación Domingo Martínez (FDM-2003) and MCyT (Ministerio de Ciencia y Tecnología, Spain; grant

BIO02002-04091-CO3-01). We also thank the Banc de Teixits Neurològics, Universitat de Barcelona-Hospital Clínic for providing the brain samples. We acknowledge Dr. Miguel A. Valverde for his critical suggestions and Dr. Gabriel Gil for his technical support. We also acknowledge to Ariadna Echenique and Labros Samartzis for their collaboration in the initial steps of this work, and to Aoife Currid for proof reading this manuscript.

SUMMARY

Amyloid ß-peptide (Aß) cytotoxicity, the hallmark of Alzheimer's disease, implicates oxidative stress in both neurons and vascular cells, particularly endothelial cells. Consequently, antioxidants have shown neuroprotective activities against Aß-induced cytotoxicity. Among the different antioxidants used both in *in vitro* and *in vivo* studies, estrogen (E_2) has garnered the most attention. Estrogen attenuated $Aß_{E22Q}$-induced toxicity in neurons but failed to protect endothelial cells. Here we show that E_2-mediated activation of endothelial nitric oxide synthase (eNOS) increases the production of nitric oxide (NO) that, under the $Aß_{E22Q}$-induced oxidative damage, results in the formation of peroxynitrite and increased nitration of tyrosine residues. Inhibition of eNOS prevents nitrotyrosination and permits E_2-mediated protection against $Aß_{E22Q}$ on endothelial cells. The main nitrotyrosinated proteins in the presence of E_2 and $Aß_{E22Q}$ were identified by MALDI-TOF mass spectrometry. These proteins are key players in the regulation of energy production, cytoskeletal integrity, protein metabolism and protection against oxidative stress. Our data highlight the potential damaging consequences of E_2 in vascular disorders dealing with oxidative stress conditions, such as cerebral amyloid angiopathy, stroke and ischemia-reperfusion conditions.

INTRODUCTION

The vascular pathology associated to Alzheimer's disease (AD) resulting in the presence of amyloid ß-peptide (Aß) fibrils in brain vessels is denominated cerebral amyloid angiopathy (CAA) (Ghiso and Frangione 2001). The hereditary cerebral hemorrhage with amyloidosis of the Dutch type (HCHWA-D) is a familiar kind of CAA. HCHWA-D patients show diffuse amyloid deposits in the brain parenchyma and mature deposits in the brain vasculature, which degenerates producing hemorrhages (Ghiso and Frangione2001). HCHWA-D is produced by a mutation in the Aß-encoding gene, which causes the replacement of Glu→Gln at position 22 ($Aß_{E22Q}$), eliciting a more fibrillogenic Aß than the wild type (Muñoz *et al.* 2002). This mutated Aß has been also demonstrated to be more toxic than the Aß wild type (Muñoz *et al.* 2002).

The cell damage induced by Aß involves oxidative stress (Butterfield and Bush 2004). Thus *post mortem* studies showed oxidative markers in lipids, proteins and nucleic acids from AD patients (Miranda *et al.* 2000). Moreover, *in vitro* studies have demonstrated the involvement of oxidative stress in Aß-mediated cytotoxicity in neuronal (Behl 1997) and vascular cells (Muñoz *et al.* 2002). Endothelial dysfunction induced by Aß can be increased by the formation of the powerful free radical peroxynitrite ($ONOO^{\cdot-}$), resulting from the reaction of nitric oxide (NO) with superoxide ($O_2^{\cdot-}$) (Radi 2004). One of the consequences of large amounts of peroxynitrite is protein nitrotyrosination, which compromises cellular function and viability (Radi 2004). Interestingly, massive peroxynitration has been reported in brains from AD patients (Castegna *et al.* 2003).

Consequent with the involvement of oxidative stress in the pathophysiology of AD, many therapeutic approaches based on the use of antioxidants have been tested (Miranda *et al.* 2002). Vitamin E (vit E) and other antioxidants protect against Aß-cytotoxicity in neuronal (Butterfield *et al.* 1999) and vascular cells (Miranda *et al.* 2002). The sex hormone 17ß-estradiol (E_2), also protects against Aß challenge in neurons (Bonnefont *et al.* 1998), but

fails to protect endothelial cells challenged with Aß or H_2O_2 (Muñoz *et al.* 2002). E_2 might have many roles in neuroprotection (Behl 2002), including its neurotrophic (Garcia-Segura *et al.* 2001) and antioxidant properties (Moosmann and Behl 1999). E_2 also presents pleiotropic beneficial effects on the vasculature (Mendelsohn 2002b), particularly favoring vasodilatation by increasing NO bioavailability (Chen *et al.* 1999). However, this effect might turn deleterious under conditions of increased oxidative stress, when NO production by E_2 stimulation could result in excessive peroxynitrite formation.

In the present work we have studied the effect of E_2 on $Aß_{E22Q}$-mediated cytotoxicity in vascular smooth muscle cells (HA-VSMCs) and endothelial cell (HUVECs) and primary cultures of mouse cortical neurons and glial cells. We have used 10 µM E_2 because the concentration of E_2 acting as an antioxidant *in vitro* is in the micromolar range (Behl 2002), which is far from the physiological circulating levels but close to the E_2 concentration in microenvironments as accounts in cell membranes where it can be massively inserted. Cell viability, the presence of apoptotic markers and identification of nitrotyrosinated proteins were also assayed in HUVECs challenged with $Aß_{E22Q}$ and treated with E_2 in the presence of the NO-synthase (NOS) inhibitor N^G-nitro-L-arginine (L-NNA) or with the NO scavenger 4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO), which reacts with NO stoichiometrically and avoid its bioavility without affecting NO synthase activity (Akaike *et al.* 1993).

EXPERIMENTAL PROCEDURES

Materials - Synthetic Aß peptide corresponding to the human $Aß_{1-40}$ Dutch variant that contains a glutamic acid to glutamine substitution ($Aß_{E22Q}$) was purchased from Oncogene (Darmstadt, Germany). $Aß_{E22Q}$ produces more stable fibrils than Aß wild type but there are not differences in the amyloidogenic properties of both Aß types (Muñoz *et al.* 2002). Amyloid fibrils were obtained and characterized as previously described (Muñoz *et al.* 2002). $Aß_{E22Q}$ fibrils were

used at a final concentration of 0.125 µM on HUVECs, 0.25 µM on HA-VSMCs and 1.25 µM on neuronal and glial cells in order to obtain a viability around 60 %. All media and culture products were purchased from Gibco BRL (Paisley, UK). Experiments were performed with phenol red- and serum-free media. All chemicals were obtained from Sigma (St Louis, MO) unless otherwise were indicated.

Cell cultures - Human umbilical venule endothelial cells (HUVECs) were grown in M-199 medium supplemented with 10% fetal bovine serum (FBS), 3.2 mM glutamine and antibiotics (100 units/ml penicillin and 10^{-6} µg/ml streptomycin). Mouse lung capillary endothelial cells (1G11 ECs) (Dong *et al.* 1997) were grown in DMEM supplemented with 20% FBS, 150 µg/ml of endothelial cell growth supplement (Becton-Dickinson, Bedford, Mass), 100 µg/ml of heparin, 1% non-essential amino acids and antibiotics. Porcine aortic endothelial cells (PAECs) were grown in DMEM supplemented with 10% FBS and antibiotics. Murine hemangioma endothelial cells (Py-4-1 ECs) were grown in DMEM supplemented with 10% FBS, 2 ng/ml of bFGF and antibiotics. Human aortic vascular smooth muscle cells (HA-VSMCs) were grown in RPMI MCDB 131 medium supplemented with 5% FBS, 5×10^{-7} g/l EGF, 1.5×10^{-6} g/l b-FGF, 5 g/l insulin, 2 mM L-glutamine and antibiotics. Mouse cortical neurons were isolated from 18-day-old OS-1 mouse embryos and cultured in DMEM plus B27 (Gibco BRL) on poly-L-lysine coated plates. Glial cultures were obtained from 2-day old mice and cultured in DMEM plus 10% FBS. Cortical neurons were used after 6 days in culture and glial cells after the second passage. Animals were manipulated according to the Council of the European Union (86/6091 EU) and to the Ethical Committee of the Institut Municipal d'Investigació Mèdica-Universitat Pompeu Fabra (IMIM-UPF).

Brain samples - Brain tissue sections were supplied by the Banc de Teixits Neurològics (Serveis Científico-Tècnics, Hospital Clínic, Universitat de Barcelona). The procedure was approved by the Ethical Committee of the IMIM-UPF. 5 µm brain sections were obtained from

the frontal cortex of 3 control males, 7 control females, 6 males with AD (stage VI) and 6 females with AD (stage VI), none receiving hormone replacement therapy.

Cell viability assay - Cells were seeded in 96-well plates at a density of 8,000 cells/100 µl (HUVECs and HA-VSMCs) or 20,000 cells/100 µl (cortical neurons and glial cells) per well. Cells were challenged with $Aß_{E22Q}$, 10 µM H_2O_2 or PBS. 0.1 µM or 10 µM E_2 was added 1 h before $Aß_{E22Q}$ fibrils or H_2O_2. 100 µM L-NNA or 10 µM PTIO was added 1 h before E_2 treatment. Trolox (a water-soluble analog of vit E that maintains the OH in the mesomeric ring where the free radical scavenger activity is located and lack of the hydrophobic aliphatic chain of vit E (McClain *et al.* 1995)) was used at 100 µM. 17α-estradiol was used at 1 µM. 0.1 µM estrogen receptor (ER) antagonists ICI 182,780 (a 7 alpha-alkylamide analogue of estradiol with pure antiestrogenic activity) or tamoxifen (a nonsteroidal triphenylethylene derivative acting as a partial ER antagonist) was added 1 h before E_2. Cells were incubated for 24 h at 37°C and cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction method. Assays were run in triplicate, determined in a Microplate Reader (Model 550, Bio-Rad, Hercules, CA) and data expressed as percentage of control.

Apoptosis Assay - $4x10^4$ HUVECs were seeded on 1% poly-L-lysine coated coverslips and treated for 6 h at 37ºC with $Aß_{E22Q}$, E_2 and L-NNA or PTIO. Coverslips were processed according the DeadEnd™ Colorimetric TUNEL System (Promega, Madison, WI). Representative digital images were taken with a Leica DMRB and analyzed with CCD Leica DC300F (Heidelberg, Germany).

Akt phosphorylation - $1.5x10^6$ HUVECs were seeded on 90 mm plates and treated for 24 h at 37ºC with $Aß_{E22Q}$ or E_2. Cells were lysed and 75 µg protein per sample was run in 10% SDS-PAGE. Blotted nitrocellulose membranes were incubated with 1:500 mouse anti-phospho-Akt (Ser473) monoclonal antibody (Ab) (Cell Signaling, Beverly, MA) overnight

at 4ºC or rabbit anti-ß-actin monoclonal Ab for 1 h at room temperature as loading control. It was followed by the incubation with 1:5,000 sheep anti-mouse peroxidase-conjugated polyclonal Ab or donkey anti-rabbit peroxidase-conjugated polyclonal Ab (Amersham Bioscience, Barcelona, Spain) for 1 h at room temperature. Bands were visualized using the enhancer chemiluminescence substrate Super Signal (Pierce, Rockford, IL) and Amersham Bioscience Hyperfilm ECL kit.

Nitrotyrosine immunoreactivity on endothelial cells - 4×10^4 HUVECs, PAECs, 1G11 ECs and Py-4-1 ECs were seeded in 1% poly-L-lysine coated coverslips and treated for 24 h at 37ºC with $Aß_{E22Q}$, E_2, sodium nitroprussiate (SNP) and L-NNA or PTIO. Cells were fixed and incubated for 2 h at room temperature with 1:500 rabbit anti-nitrotyrosine polyclonal Ab (Molecular Probes, Leiden, The Netherlands) followed by incubation with 1:500 Alexa fluor 488 goat anti-rabbit polyclonal Ab for 1 h at room temperature Digital images were taken with a Leica TCS SP confocal microscope and analyzed with Leica confocal software (Heidelberg, Germany).

Brain sample staining - Sections were treated with alkaline solution followed by Congo red staining. The following sections were treated with 4% H_2O_2 and incubated with 1:500 rabbit anti-nitrotyrosine polyclonal Ab for 2 h at room temperature followed by the incubation with 1:5,000 biotinilated goat anti-rabbit polyclonal Ab (DAKO, Glostrup, Denmark) for 1 h at room temperature Slides were incubated with Streptavidin-HRP (Zymed laboratories, San Francisco, CA) and treated with Peroxidase Substrate Kit DAB (Vector, Burlingame CA). Samples were counterstained with hematoxylin, dehydrated and fixed with Eukitt (O.Kindler GmbH &CO, Fribourg, Switzerland). Representative digital images were taken and analyzed as described above.

NO assay - 1.5×10^6 HUVECs seeded in 90 mm plates were treated with $Aß_{E22Q}$, E_2 and L-NNA or PTIO for 24 h. Cells were lysed and protein concentration determined by the

Bio-Rad Protein Assay. NO was measured (40 µl samples in triplicate) using a nitrate/nitrite colorimetric assay kit (Cayman, Ann Arbor, MI). NO production was calculated to the amount of protein.

Identification of nitrotyrosinated proteins - $1.2x10^6$ HUVECs were seeded in 90 mm plates and treated for 24 h at 37ºC with $Aß_{E22Q}$, E_2 and L-NNA or PTIO. Cells were lysed in 100 µL buffer (7 M urea, 2 M thiourea, 4% CHAPS, 2% IPG buffer 3-10 NL, 1% DTT and protease inhibitors), sonicated, acetone precipitated and subsequently centrifuged.

2D gel electrophoresis - 200 µg protein were dissolved up to 125 µL buffer (7 M urea, 2 M thiourea, 4% CHAPS, 0.5% IPG buffer 3-10 NL, and 1.2 µL Destreak reagent). Isolectric focusing was done at 20ºC. The rehydration step was carried out by 1h 200 V and followed by 250 Vh 500 V, 500 Vh 1000 V, 40 min-gradient until 5,000 V, and 4h 5,000 V. Gel strips were equilibrated in DTT and iodoacetamide-based buffers and loaded onto 12% SDS-PAGE. Duplicate gels were run for each sample, one for Western blot and another for protein identification.

Western Blot - Nitrocellulose membranes were incubated for 2 h at room temperature with 1:500 rabbit anti-nitrotyrosine polyclonal Ab and for 1 h at room temperature with 1:5,000 donkey anti-rabbit peroxidase-conjugated polyclonal Ab (Amersham Bioscience). Bands were visualized as described above. The protein identification was performed in gels stained with Coomassie R-350. Bands matching those shown to contain nitrotyrosine by Western blot in the duplicate set (see above) were unstained by sequential hydration/dehydration steps with 0.1 M NH_4HCO_3 (pH 8) and acetonitrile respectively. Gel plugs were dried in a Speed-Vac for 5 min. Each spot was treated with 100 ng sequencing-grade trypsin in 50 mM NH_4HCO_3 and incubated for 30 min at 4ºC and then overnight at 37ºC. 10 µl digested sample were desalted with a Poros R2 column (ABI). Peptide mass fingerprints were obtained in a Voyager DE-STR MALDI-TOF mass spectrometer (Applied Biosystems, Foster City, CA) and searched against

the NCBI and Swiss-Prot protein databases using the MASCOT search engine. Peptide mass fingerprinting used the assumption that peptides were monoisotopic, oxidized at Met residues and carbamidomethylated at Cys residues. A mass tolerance of 50 ppm was the window error allowed for matching the peptide mass values. .

Statistical analysis - Data are expressed as the mean ± SEM of the values from the number of experiments as indicated in the corresponding figures. Data were evaluated statistically by using the Student´s *t*-test or the one way ANOVA test followed by Bonferroni's post-hoc analysis. The level of significance was $p < 0.05$.

RESULTS

E_2-mediated protection against $Aß_{E22Q}$ cytotoxicity in endothelial cells requires low NO bioavailability - $Aß_{E22Q}$ fibrils from the Dutch variant induced marked cytotoxicity in vascular and neuronal cells (Fig. 1). E_2 reverted the cytotoxic effect of $Aß_{E22Q}$ on cortical neurons and HA-VSMCs (Fig. 1A). However, it failed to revert $Aß_{E22Q}$ toxicity on HUVECs (Fig. 1B). One possible explanation for the differential protective effect of E_2 is related to NO bioavailability. Under physiological conditions NO is a powerful vasodilator but under oxidative conditions it becomes harmful to the cells due to peroxynitrite formation. E_2 is a well-known activator of eNOS (Chen *et al.* 1999). Therefore, we evaluated the protective effect of E_2 against $Aß_{E22Q}$ in the presence of the NOS inhibitor L-NNA and the NO scavenger PTIO (Fig. 1B). Under both conditions, E_2 significantly reduced the $Aß_{E22Q}$-mediated cytotoxicity in HUVECs measured by the MTT assay ($P<0.05$). On the other hand, the presence of L-NNA or PTIO did not modify the cell viability of HA-VSMCs or cortical neurons (Fig. 1A). Interestingly, experiments carried out in mouse glial cells, which express iNOS that is not regulated by E_2 (Fulton *et al.* 1999), showed that E_2 increased cell viability (75±9%) in response to $Aß_{E22Q}$ (57±7%), and this

protection was further increased (86±13%) in the presence of 100 µM aminoguanidine, a specific inhibitor of iNOS.

$Aß_{E22Q}$ toxicity, like oxidative stress in general, has been associated with the induction of apoptotic cell death (Muñoz, Opazo, Gil-Gomez, Tapia, Fernandez, Valverde, and Inestrosa2002). Accordingly, the presence of apoptotic endothelial cells in response to $Aß_{E22Q}$ and the different treatments was tested using the TUNEL assay (Fig. 1C). Under control conditions no apoptotic HUVECs were observed in a representative optical field. Treatment with $Aß_{E22Q}$ induced the appearance of numerous apoptotic cells that was not prevented by E_2, but was reverted by coincubation with E_2 plus L-NNA or PTIO. Altogether, the results obtained using MTT and TUNEL assays indicate that the protective effect of E_2 against $Aß_{E22Q}$ is only achieved by inhibiting the eNOS or reducing the availability of NO with a NO scavenger. The same pattern of response was obtained when HUVECs were incubated with 10 µM H_2O_2, a prooxidant stimulus (Fig. 1D). The most significant protection against $Aß_{E22Q}$ toxicity was provided by Trolox, a powerful antioxidant (Fig. 1E).

ER-independent protection by E_2 - Akt phosphorylation was observed in HUVECs exposed to E_2 (Fig. 2E). Slight activation of Akt was also observed in cells treated with $Aß_{E22Q}$. Since the PI3K/Akt pathway has been involved in the maintenance of cell survival (Franke *et al.* 2003), this effect could be related to the triggering of protective mechanisms.

The role of ER_α in the effect of E_2 in $Aß_{E22Q}$-mediated cytotoxicity was assayed in HUVECs exposed to $Aß_{E22Q}$ or $Aß_{E22Q}$ plus E_2 in the presence of the ER_α antagonists ICI 182,780 and tamoxifen (Fig. 2A). ER inhibition provides protection by E_2 against the $Aß_{E22Q}$ challenge in HUVECs ($P<0.05$). Under these conditions, eNOS cannot be activated and the increased NO supply is prevented. On the other hand, the use of ER inhibitors did not modify the protective effect of E_2 on HA-VSMCs (Fig. 2B). Since E_2 activates eNOS at physiological

concentrations, E_2 was also assayed at 0.1µM (Fig. 2C), but protection was not obtained in the presence of L-NNA or PTIO. At this low concentration E_2 lacks its antioxidant ability. Accordingly, HUVECs challenged with $A\beta_{E22Q}$ in the presence of 1 µM 17α-estradiol (Fig. 2D), which does not bind ER but maintains the antioxidant properties, were protected. Altogether, the data shown suggest that E_2 protection is independent of its binding to the ER.

$A\beta_{E22Q}$ and $A\beta_{E22Q}$ plus E_2 induce nitrotyrosination of protein residues that can be reverted by NO inhibitors - Excessive NO production induced by E_2-dependent activation of eNOS reduces the protective effect of E_2 in HUVECs challenged with $A\beta_{E22Q}$. This finding could be related to the production of peroxynitrites in a prooxidant environment. Therefore, we have studied protein nitrotyrosination in HUVECs (Fig. 3A, left panels). We observed that in the absence of oxidative challenge HUVECs presented a low level of nitrotyrosination, determined by confocal immunofluorescence with an anti-nitrotyrosine Ab. $A\beta_{E22Q}$ induced a significant increase in nitrotyrosination that further increased in the presence of E_2 and was reverted by L-NNA or PTIO. Identical results were obtained with other endothelial cells: 1G11 ECs (Fig. 3B), PAECs and Py-4-1 ECs (data not shown). Moreover, $A\beta_{E22Q}$ challenged with a NO donor (sodium nitroprussiate) mimics the result obtained with $A\beta_{E22Q}$ plus E_2 treatment on HUVECs (Fig. 3D). The nitrotyrosination levels were transformed into a pseudocolor scale (Fig. 3A, right panels) and represented quantitatively as fluorescence arbitrary units (Fig. 3C). Figure 3C also shows the NO levels as percentage relative to control conditions. $A\beta_{E22Q}$ challenge, in addition to increasing nitrotyrosination of HUVECs, reduced the NO level, most likely due to the formation of peroxynitrite following the reaction of NO with the superoxide anion generated by the presence of $A\beta_{E22Q}$. The highest levels of nitrotyrosination were observed in HUVECs exposed to $A\beta_{E22Q}$ plus E_2, in agreement with the highest NO production. Both nitrotyrosine fluorescence and NO levels were reduced in cells exposed to L-NNA or PTIO in

the presence of Aß$_{E22Q}$ plus E_2. Nitrotyrosine formation has been described in AD brains (Castegna *et al.* 2003). Therefore, we also evaluated nitrotyrosination in the frontal cortex vessels from AD patients (Fig. 3E). Immunohistochemical studies revealed the absence of either Aß vascular deposits or nitrotyrosination reactivity in sequential sections from controls without AD (Fig. 3E, top panels). In constrast, in brain sections from AD patients, Aß vascular deposits correlating with protein nitrotyrosination were observed (Fig. 3E, bottom panels), suggesting that Aß-mediated vascular damage is associated to protein nitrotyrosination. No differences in the presence of nitrotyrosination associated to amyloid deposits were observed attending to the gender.

Identification of nitrotyrosinated proteins in HUVECs - In order to investigate the main target proteins for nitrotyrosination, we carried out a comparative two-dimensional elecrophoretic analysis by western blot (Fig. 4). While no nitrotyrosine immunoreactivity was detected in control HUVECs (Fig. 4A), clear nitrotyrosination was present in HUVECs treated with Aß$_{E22Q}$ (Fig. 4B), which was even more prominent in cells treated with Aß$_{E22Q}$ and E_2 (Fig. 4C). The addition of L-NNA (Fig. 4D) or PTIO (Fig. 4E) significantly reduced the nitrotyrosine immunoreactivity. The nitrotyrosinated proteins identified in the presence of Aß$_{E22Q}$ or Aß$_{E22Q}$ plus E_2 are listed in Table 1.

DISCUSSION

Estrogens have been widely proposed as neuroprotective agents in a variety of *in vivo* and *in vitro* models (Behl 2002;Mendelsohn 2002a). Moreover, clinical trials have associated E_2 with the retardation of the onset and progression of AD (Kawas *et al.* 1997;Tang *et al.* 1996) although other studies offered a less optimistic scenario (Grodstein *et al.* 2000;Rapp *et al.* 2003). The putative neuroprotective effects of E_2 in AD involve decreased Aß production,

enhanced synthesis of choline-acetyltransferase, promotion of neuronal growth (Garcia-Segura *et al.* 2001), activation of potassium channels leading to vasodilatation (Valverde *et al.* 1999) and antioxidant properties (Moosmann and Behl 1999). The antioxidant effect of E_2 is independent of its interaction with ERs or other estrogen binding sites and is related to the phenolic OH group (Moosmann and Behl1999), a chemical structure also present in α-tocopherol. Antioxidants inhibit membrane lipid peroxidation elicited by free radicals (Butterfield *et al.* 1999) as well as the intracellular damage triggered by Aß (Behl *et al.* 1994).

Our study shows a cell type-dependent protective effect of estrogen against $Aß_{E22Q}$-mediated cytotoxicity. Estrogen is able to protect cortical neurons, glial cells and smooth muscle cells against $Aß_{E22Q}$, but fails to protect endothelial cells. Estrogen uses both genomic and alternative (non-genomic) mechanisms of action that might implicate the known ER (ER_{α} and ER_{β}) (Nadal *et al.* 2001) or be ER-independent (e.g., its antioxidant effect) (Behl 2002). In the endothelium, eNOS produces NO by the conversion of L-arginine to L-citrulline (Radi 2004). eNOS is activated by E_2 via the ER_{α} and PI3K/Akt pathway within caveoli signaling microdomains (Mendelsohn 2002a). HUVECs express ER_{α} that colocalizes with caveolin-1 (data not shown). The lack of protection on endothelial cells is related to the E_2-dependent activation of eNOS and the production of NO as inhibition of ER or eNOS enables the protective effect of E_2. These results suggest that the protective role of E_2 is independent of its binding to the ER but related to its antioxidant properties. The fact that none of the cells treated with E_2 conferred protection against $Aß_{E22Q}$ at nanomolar concentrations is also suggestive of a mechanism of action different from its interaction with ERs. NO reacts with the superoxide anion producing highly reactive peroxynitrite (Radi 2004) which causes the protein nitrotyrosination, a marker of cell damage reported in neurons and glial cells from AD brains (Castegna *et al.* 2003). We have found that vascular amyloid deposits correlate with nitrotyrosination in brain vessels from AD patients. These findings are in agreement with previous studies describing endothelial cell degeneration in CAA (Miyakawa *et al.* 1997) and

dysfunction of the blood-brain barrier (Wisniewski *et al.* 2000). No difference in the level of nitrotyrosination associated to amyloid plaques was observed between samples from both genders. This fact may be explained based on the low levels of circulating oestrogens present in postmenopausal women (Orshal and Khahil 2004).

Aß fibrils act as a source of superoxide anion (Butterfield and Bush 2004), which can react with the basal levels of NO, due to the high affinity of NO for the superoxide anion (Huie and Padmaja 1993), triggering nitrotyrosination. We have observed protein nitrotyrosination in HUVECs exposed to $Aß_{E22Q}$ alone. Higher levels of nitrotyrosination were observed in HUVECs exposed to $Aß_{E22Q}$ and E_2, an effect reversed by PTIO and L-NNA. However, no increase in cell viability was seen in the presence of $Aß_{E22Q}$ and PTIO or L-NNA suggesting that the main source of cell damage is provided by the Aß-induced oxidative stress, rather than nitrotyronisation. Alternatively, it might be necessary to reach a nitrotyrosination threshold in order to produce cell death, as previously suggested (Paris *et al.* 1998).

In this study, we have identified several proteins that are nitrotyrosinated under the conditions we have tested (Table 1). They are functionally related to the regulation of energy production, cytoskeletal integrity, protein metabolism and protection against oxidative stress. The functions of these proteins should be inhibited since nitrotyrosination has been mainly associated with the loss of function and subsequent labeling for degradation via the proteasome (Grune *et al.* 1998).

One of the most striking proteins to be nitrotyrosinated, TIM, is involved in the interconversion of dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-phosphate (GA3P) in the glycolytic pathway. If TIM function is altered, DHAP will be accumulated in the cell. Interestingly, inherited TIM deficiency leads to abnormal accumulation of DHAP and chronic neurodegeneration and has been also associated to degeneration of vascular endothelial

cells (Ahmed *et al.* 2003). It has also been proposed that a defective TIM could form pathological aggregates with microtubules (Orosz *et al.* 2000).

Mitochondrial HSP75 plays an important role in preserving the integrity of mitochondria. This chaperone assists the folding of imported proteins to this organelle, as well as those proteins altered by oxidative stress. The inactivation of this enzyme is a key step in producing the mitochondrial impairment, failure of energetic metabolism and cerebral hypoperfusion (Aliev *et al.* 2003).

The non-selenium GluPx (or 1-cys peroxiredoxin) is a cytosolic bifunctional enzyme with peroxidase and PLA_2-like activities (Chen *et al.* 2000). It hydrolyzes phospholipid hydroperoxides to free fatty acids hydroperoxides, playing an important role in preserving the membrane function and integrity (Fisher *et al.* 1999). Its nitrotyrosination could produce an increase in the oxidative injury.

TCP-1, is a cytosolic chaperone that assists in the folding of tubulin, actin and vinculin. The abnormal folding of cytoskeletal proteins in endothelial cells might determine alterations in cell adhesion, loss of the blood-brain barrier selectivity and endothelial apoptosis (Li *et al.* 1999).

Eukaryotic translation elongation factor 2 (ef-2) is responsible for the elongation phase during protein synthesis. It has been reported that oxidative stress reduces protein synthesis (Patel *et al.* 2002), thereby nitrotyrosination of ef-2 might result in reduced protein synthesis.

Finally, 26S proteasome is one of the main degradation systems inside the cell (Goldberg 2003). The nitrotyrosination of 26S proteasome could alter the degradation of proteins in a critical situation as oxidative stress.

In conclusion, our study shows that the beneficial effect of E_2 against Aβ-mediated cell damage in endothelial cells is ER-independent, while its endothelial harmful effect is through its interaction with ER, via NO production and protein nitrotyrosination. Although there is not

increased cell death in the presence of $A\beta_{E22Q}$ and E_2 compared to $A\beta_{E22Q}$ alone, there is a significant increase of nitrotyrosination in enzymes involved in glucose metabolism, energetic balance, repairing systems, protein degradation and cytoskeleton, which most likely compromise cell functions.

Estrogen effects are complex, with plenty of preliminary studies praising its neuro- and vascular-protective effects (Behl 2002; Mendelsohn 2002a), whereas clinical trial have yielded disappointing results (Grodstein *et al.,* 2000; Rapp *et al.,* 2003; Hippisley-Cox *et al.* 2003; Viscoli *et al.* 2001). Our data suggest possible damaging effects of E_2 in vascular disorders dealing with oxidative stress conditions, such as cerebral amyloid angiopathy (Muñoz *et al.* 2002), stroke and ischemia-reperfusion conditions (Gilgun-Sherki *et al.* 2002), where an overproduction of NO can be harmful (Hobbs *et al.* 1999). They might also cast light on the mechanisms that will explain recently reported worsening of the injury caused by recurrent cerebral ischemia in women undergoing hormone replacement therapy (Viscoli *et al.* 2001;Rossouw *et al.* 2002).

REFERENCE LIST

Ahmed N, Battah S, Karachalias N *et al*. Increased formation of methylglyoxal and protein glycation, oxidation and nitrosation in triosephosphate isomerase deficiency. Biochim.Biophys.Acta 2003; 1639: 121-132.

Akaike T, Yoshida M, Miyamoto Y *et al*. Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/.NO through a radical reaction. Biochemistry 1993; 32: 827-832.

Aliev G, Smith MA, Obrenovich ME, de la Torre JC, Perry G. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease. Neurotox.Res. 2003; 5: 491-504.

Behl C. Amyloid beta-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tissue Res. 1997; 290: 471-480.

Behl C. Oestrogen as a neuroprotective hormone. Nat.Rev.Neurosci. 2002; 3: 433-442.

Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994; 77: 817-827.

Bonnefont AB, Muñoz FJ, Inestrosa NC. Estrogen protects neuronal cells from the cytotoxicity induced by acetylcholinesterase-amyloid complexes. FEBS Lett. 1998; 441: 220-224.

Butterfield DA, Bush AI. Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol.Aging 2004; 25: 563-568.

Butterfield DA, Koppal T, Subramaniam R, Yatin S. Vitamin E as an antioxidant/free radical scavenger against amyloid beta-peptide-induced oxidative stress in neocortical synaptosomal membranes and hippocampal neurons in culture: insights into Alzheimer's disease. Rev.Neurosci. 1999; 10: 141-149.

Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J.Neurochem. 2003; 85: 1394-1401.

Chen JW, Dodia C, Feinstein SI, Jain MK, Fisher AB. 1-Cys peroxiredoxin, a bifunctional enzyme with glutathione peroxidase and phospholipase A2 activities. J.Biol.Chem. 2000; 275: 28421-28427.

Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J.Clin.Invest 1999; 103: 401-406.

Dong QG, Bernasconi S, Lostaglio S *et al*. A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler.Thromb.Vasc.Biol. 1997; 17: 1599-1604.

Fisher AB, Dodia C, Manevich Y, Chen JW, Feinstein SI. Phospholipid hydroperoxides are substrates for non-selenium glutathione peroxidase. J.Biol.Chem. 1999; 274: 21326-21334.

Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003; 22: 8983-8998.

Fulton D, Gratton JP, McCabe TJ *et al*. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 597-601.

Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotection by estradiol. Prog.Neurobiol. 2001; 63: 29-60.

Ghiso J, Frangione B. Cerebral amyloidosis, amyloid angiopathy, and their relationship to stroke and dementia. J.Alzheimers.Dis. 2001; 3: 65-73.

Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D. Antioxidant therapy in acute central nervous system injury: current state. Pharmacol.Rev. 2002; 54: 271-284.

Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003; 426: 895-899.

Grodstein F, Chen J, Pollen DA *et al*. Postmenopausal hormone therapy and cognitive function in healthy older women. J.Am.Geriatr.Soc. 2000; 48: 746-752.

Grune T, Blasig IE, Sitte N, Roloff B, Haseloff R, Davies KJ. Peroxynitrite increases the degradation of aconitase and other cellular proteins by proteasome. J.Biol.Chem. 1998; 273: 10857-10862.

Hippisley-Cox J, Pringle M, Crown N, Coupland C. A case-control study on the effect of hormone replacement therapy on ischaemic heart disease. Br.J.Gen.Pract. 2003; 53: 191-196.

Hobbs AJ, Higgs A, Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu.Rev.Pharmacol.Toxicol. 1999; 39: 191-220.

Huie RE, Padmaja S. The reaction of no with superoxide. Free Radic.Res.Commun. 1993; 18: 195-199.

Kawas C, Resnick S, Morrison A *et al*. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997; 48: 1517-1521.

Li AE, Ito H, Rovira II *et al*. A role for reactive oxygen species in endothelial cell anoikis. Circ.Res. 1999; 85: 304-310.

McClain DE, Kalinich JF, Ramakrishnan N. Trolox inhibits apoptosis in irradiated MOLT-4 lymphocytes. FASEB J. 1995; 9: 1345-1354.

Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am.J.Cardiol. 2002a; 90: 3F-6F.

Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. Am.J.Cardiol. 2002b; 89: 12E-17E.

Miranda S, Opazo C, Larrondo LF *et al*. The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease. Prog.Neurobiol. 2000; 62: 633-648.

Miyakawa T, Katsuragi S, Higuchi Y *et al*. Changes of microvessels in the brain with Alzheimer's disease. Ann.N.Y.Acad.Sci. 1997; 826: 428-432.

Moosmann B, Behl C. The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc.Natl.Acad.Sci.U.S.A 1999; 96: 8867-8872.

Muñoz FJ, Opazo C, Gil-Gomez G *et al*. Vitamin E but not 17beta-estradiol protects against vascular toxicity induced by beta-amyloid wild type and the Dutch amyloid variant. J.Neurosci. 2002; 22: 3081-3089.

Nadal A, Diaz M, Valverde MA. The estrogen trinity: membrane, cytosolic, and nuclear effects. News Physiol.Sci. 2001; 16: 251-255.

Orosz F, Wagner G, Liliom K *et al*. Enhanced association of mutant triosephosphate isomerase to red cell membranes and to brain microtubules. Proc.Natl.Acad.Sci.U.S.A 2000; 97: 1026-1031.

Orshal JM, Khahil RA. Gender, sex hormones, and vasculature tone. Am.J. Physiol.Regul.Integr.Comp.Physiol. 2004; 286: R233-R249.

Paris D, Parker TA, Town T *et al*. Role of peroxynitrite in the vasoactive and cytotoxic effects of Alzheimer's beta-amyloid1-40 peptide. Exp.Neurol. 1998; 152: 116-122.

Patel J, McLeod LE, Vries RG, Flynn A, Wang X, Proud CG. Cellular stresses profoundly inhibit protein synthesis and modulate the states of phosphorylation of multiple translation factors. Eur.J.Biochem. 2002; 269: 3076-3085.

Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc.Natl.Acad.Sci.U.S.A 2004; 101: 4003-4008.

Rapp SR, Espeland MA, Shumaker SA *et al*. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2663-2672.

Rossouw JE, Anderson GL, Prentice RL *et al*. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.

Tang MX, Jacobs D, Stern Y *et al*. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-432.

Valverde MA, Rojas P, Amigo J *et al*. Acute activation of Maxi-K channels (hSlo) by estradiol binding to the beta subunit. Science 1999; 285: 1929-1931.

Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N.Engl.J.Med. 2001; 345: 1243-1249.

Wisniewski HM, Wegiel J, Vorbrodt AW, Mazur-Kolecka B, Frackowiak J. Role of perivascular cells and myocytes in vascular amyloidosis. Ann.N.Y.Acad.Sci. 2000; 903: 6-18.

Table 1: Idendified Nitrotyrosinated Proteins

	Protein Nº	M_r (Da)	pI	SC (%)	Function
1	Triose phosphate isomerase (chain A)	26,807 (T) 28,000 (O)	6.51 (T) 6.40 (O)	69	Glycolysis (Cyt)
2	Peroxiredoxin 6, non glutathione peroxidase	25,133 (T) 28,000 (O)	6.00 (T) 6.20 (O)	54	Detoxifycation of free radicals (Cyt and Lys)
3	26S Proteasome	45,768 (T) 40,000 (O)	7.11 (T) 6.60 (O)	44	Protein degradation (Cyt and Nuc)
4	TCPB (t complex protein 1, ß subunit)	57,794 (T) 54,000 (O)	6.01 (T) 6.00 (O)	63	Chaperone of actin and tubulin (Cyt)
5	MTHSP75	73,920 (T) 70,000 (O)	5.87 (T) 5.70 (O)	17	Chaperone of mitochondrial proteins (Mit)
6	Metavinculin	124,161 (T) 116,000 (O)	5.51 (T) 5.90 (O)	25	Cytoskeleton (Submemb)
7	Eukaryotic translation elongation factor 2	96,246 (T) 96,000 (O)	6.41 (T) 6.60 (O)	21	Protein translation (Cyt)

Cyt, cytoplasmic; Lys, lysosomal; Nuc, nuclear; Mit, mitochondrial; O, observed; SC, sequence coverage; Submemb, submembranal; T, theoretical.

FIGURE LEGENDS

Fig. 1. **Effect of E_2 in Aß-mediated cytotoxicity.** 10 µM E_2 protected HA-VSMCs and cortical neurons (A) against 0.25 µM (for HA-VSMCs) and 1.25 µM (for neurons) $A\beta_{E22Q}$ independently of 100 µM L-NNA and 10 µM PTIO. Data are mean ± SEM values of 3-7 experiments. HUVECs were challenged with 0.125 µM $A\beta_{E22Q}$ fibrils (B) and protection with 10 µM E_2 was obtained only when NO inhibitors were present. Data are mean ± SEM values of 7-9 experiments. HUVECs were treated and stained by TUNEL method detecting apoptotic cells (C). Pictures were taken from representative experiments (n=3) performed in duplicate. HUVECs were challenged with 10 µM H_2O_2 (D) in a representative experiment performed in triplicate and protection by E_2 was obtained solely in the presence of NO inhibitors. 100 µM trolox protected $A\beta_{E22Q}$ challenge on HUVECs (E). * $p < 0.05$.

Fig. 2. **The role of ER on E_2 effect.** HUVECs (A) and HA-VSMCs (B) were challenged with $A\beta_{E22Q}$ fibrils and treated with E_2 in the presence of 0.1 µM ICI 182,780 and 0.1 µM tamoxifen. HUVECs were also challenged with $A\beta_{E22Q}$ fibrils and 0.1 µM E_2 in the presence of 100 µM L-NNA and 10 µM PTIO (C). Data are mean ± SEM values of 4-9 experiments. * $p < 0.05$. A representative study on HUVECs was carried out with $A\beta_{E22Q}$ fibrils and 1µM 17α-estradiol (D). Western-blot analysis of phospho-Akt (Ser 473) expression were performed on HUVECs after 24 hours with $A\beta_{E22Q}$ fibrils and E_2 (E).

Fig. 3. **Production of NO and nitrotyrosination in HUVECs.** Protein nitrotyrosination on HUVECs is indicated by green staining and nitrotyrosination intensity is shown using a pseudocolour scale (A). Protein nitrotryrosination on 1G11 ECs is indicated by green staining

(B). Fluorescence intensity from HUVECs is represented as arbitrary units (NT; black bars) and NO production from HUVECs (NO; grey bars) is expressed as percentage of control cells (C). Data are mean ± SEM values of 7-10 separate experiments. * $p < 0.05$. Nitrotyrosination was also studied by using a NO donor (SNP) plus $A\beta_{E22Q}$ fibrils on HUVECs (D). Colocalization of vascular amyloid deposits with nitrotyrosination (E) was performed in control and AD patient brains. Representative pictures from female brain samples are shown.

Fig. 4. **Identification of nitrotyrosinated proteins.** Western-blots show nitrotyrosinated proteins from HUVECs challenged with $A\beta_{E22Q}$ and 10 µM E_2 in the presence of 100 µM L-NNA and 10 µM PTIO. The proteins identified to be nitrotyrosinated were triose phosphate isomerase (1), peroxiredoxin 6 (2), 26S proteasome (3), T-complex protein (4), MTHSP75 (5), Metavinculin (6) and eukaryotic translation elongation factor 2 (7).

FIG.1



FIG. 2



FIG.3



FIG.4